

## General Meeting of SGIEM, Thursday 30<sup>th</sup> March 2023

Morning

**Annual meeting of the SGIEM National Network (for Members only)**

**Venue:** University of Bern, Hallerstrasse 6, 2<sup>nd</sup> Floor, in Bern

**Agenda :** see separate mailing to all members

09:15 General Meeting, Part 1

10:15 Coffee Break

10:45 General Meeting, Part 2

11:45 Lunch in Foyer

### Subgroup Meetings 12:00-13:00

<b>Seminarraum 203:</b>	12:00-13:00	SGBOND
<b>Hörraum 205 (Entrance B):</b>	12:00-13:00	Adult Group
<b>Alpenraum in WTI (GF):</b>	12:00-13:00	Dietician Group
<b>Hörraum 205 (Entrance A):</b>	12:00-13:00	Labs
<b>Foyer:</b>	12:00-13:00	PO

## General Meeting of SGIEM, Thursday 30<sup>th</sup> March 2023

Afternoon

**Scientific Symposium (open to all interested; on registration only)**

**Venue:** University of Bern, Hallerstrasse 6, 2<sup>nd</sup> Floor, in Bern

**13:15 KEYNOTE LECTURE:** Chair: Christel Tran  
***Beyond the bones: The 2023 nosology of genetic skeletal disorders and its relationship to metabolism and genetics***  
*Prof. Dr. Andrea Superti-Furga, Lausanne*

**14:15-15:05 SESSION 1: Diagnostic and Clinical Practice** – Chair: Marco Strasser

**14:15** *Christian Urzi:* Intra- and Extracellular Metabolic Investigation of Perfused Fibroblasts by Real-time NMR Allows for Better Discrimination of Mitochondrial Defects

**14:30** *Aurel T. Tankeu:* Biotinidase Deficiency: What Have We Learned in 40 Years?

**14:45** *Christina Kaufman:* Diagnostic delay in patients with cerebral creatine deficiency disorders

**15:05-15:35 Break**

**15:35-16:20 SESSION 2: SGBOND & Porphyrias**– Chair: Aurel Tankeu

**15:35** *Manuela Messikommer:* Late diagnosis of childhood-onset hypophosphatasia in an adult with recurrent fractures: the impact of enzyme replacement therapy

**15:50** *Giulio Marcionelli:* Perturbations in fatty acid metabolism and collagen production infer pathogenicity of a novel MBTPS2 variant in Osteogenesis imperfecta

**16:05** *Jasmin Barman-Aksözen:* Quality Adjusted Life Years in erythropoietic protoporphyria and other rare diseases. A patient-initiated EQ-5D feasibility study.

**16:20-17:05 SESSION 3: Potential new treatments** – Chair: Giulio Marcionelli

**16:20** *Alexander Laemmle:* Using induced pluripotent stem cell (iPSC) technology to understand the ultra-rare metabolic disease malate dehydrogenase 2 (MDH2) deficiency (MDH2D) and its potential treatment with triheptanoin

**16:35** *Gabriella Fernandes-Pires:* Rescue of myocytes and locomotor activity through intracisternal AAV9 gene therapy in a rat model of creatine transporter deficiency

**16:50** *Marco Strasser:* Individual therapeutic trial for a severe sleep disorder in a patient with mitochondrial disease using a rocking bed

**17:05 Prize best presentation / Closing Remarks** – followed by **Apéro dînatoire**